446284-56-6

Basic information

• Product Name: 1H-Pyrrolo[2,3-c]pyridine-7-carboxylic acid, 4-fluoro-
• Synonyms: 4-Fluoro-6-azaindole-7-carboxylic acid;1H-Pyrrolo[2,3-c]pyridine-7-carboxylic acid, 4-fluoro-;4-Fluoro-1H-pyrrolo[2,3-c]pyridine-7-carboxylic acid
• CAS NO: 446284-56-6
• Molecular Formula: C8H5FN2O2
• Molecular Weight: 180.1359032
• Mol File: 446284-56-6.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1H-Pyrrolo[2,3-c]pyridine-7-carboxylic acid, 4-fluoro-(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Pyrrolo[2,3-c]pyridine-7-carboxylic acid, 4-fluoro-(446284-56-6)
• EPA Substance Registry System: 1H-Pyrrolo[2,3-c]pyridine-7-carboxylic acid, 4-fluoro-(446284-56-6)

Safety Data

• Hazardous Substances Data: 446284-56-6(Hazardous Substances Data)

Usage

Derivative of pyrrolopyridine

1H-Pyrrolo[2,3-c]pyridine-7-carboxylic acid, 4-fluoro- is derived from pyrrolopyridine, which is a heterocyclic compound consisting of a pyrrole ring fused to a pyridine ring.

Contains a carboxylic acid group

The carboxylic acid group (-COOH) is a functional group present in the molecule, which gives it acidic properties.

Contains a fluorine atom

The presence of a fluorine atom (-F) in the molecule distinguishes it from similar compounds and may affect its chemical properties and reactivity.

Used as a building block in pharmaceutical industry

1H-Pyrrolo[2,3-c]pyridine-7-carboxylic acid, 4-fluorois commonly used in the pharmaceutical industry as a building block for the synthesis of various biologically active molecules.

Potential applications in drug development

1H-Pyrrolo[2,3-c]pyridine-7-carboxylic acid, 4-fluoro- has potential applications in the development of new drugs, particularly in the treatment of conditions such as cancer or inflammatory diseases.

Used in research and development

1H-Pyrrolo[2,3-c]pyridine-7-carboxylic acid, 4-fluoromay also be used in research and development for the creation of novel pharmaceutical compounds.

Upstream product

• 652160-72-0 2-bromo-5-fluoro-3-nitropyridine 
• 446284-50-0 4-fluoro-1H-pyrrolo[2,3-c]pyridine-7-carbonitrile 
• 446284-38-4 7-bromo-4-fluoro-1H-pyrrolo[2,3-c]pyridine 
• 136888-20-5 5-fluoro-2-hydroxy-3-nitropyridine 
• 51173-05-8 5-fluoropyridin-2-ol 
• 51173-04-7 5-fluoro-2-methoxypyridine 
• 6628-77-9 6-methoxy-pyridin-3-ylamine 
• 446284-54-4 C₉H₅FN₄O 

Downstream Products

• 959321-16-5 C₂₂H₂₀FN₅O₄ 
• 959321-17-6 C₂₁H₁₈FN₅O₄ 

Relevant articles and documents

Field-based affinity optimization of a novel azabicyclohexane scaffold HIV-1 entry inhibitor

Small-molecule HIV-1 entry inhibitors are an extremely attractive therapeutic modality. We have previously demonstrated that the entry inhibitor class can be optimized by using computational means to identify and extend the chemotypes available. Here we demonstrate unique and differential effects of previously published antiviral compounds on the gross structure of the HIV-1 Env complex, with an azabicyclohexane scaffolded inhibitor having a positive effect on glycoprotein thermostability. We demonstrate that modification of the methyltriazole-azaindole headgroup of these entry inhibitors directly effects the potency of the compounds, and substitution of the methyltriazole with an amine-oxadiazole increases the affinity of the compound 1000-fold over parental by improving the on-rate kinetic parameter. These findings support the continuing exploration of compounds that shift the conformational equilibrium of HIV-1 Env as a novel strategy to improve future inhibitor and vaccine design efforts.

Inhibitors of human immunodeficiency virus type 1 (HIV-1) attachment. 12. Structure-activity relationships associated with 4-fluoro-6-azaindole derivatives leading to the identification of 1-(4-benzoylpiperazin-1-yl)-2-(4- fluoro-7-[1,2,3]triazol-1-yl-1H-

A series of highly potent HIV-1 attachment inhibitors with 4-fluoro-6-azaindole core heterocycles that target the viral envelope protein gp120 has been prepared. Substitution in the 7-position of the azaindole core with amides (12a,b), C-linked heterocycl

Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives

This invention provides compounds having drug and bio-affecting properties, their pharmaceutical compositions and method of use. In particular, the invention is concerned with azaindoleoxoacetyl piperazine derivatives. These compounds possess unique antiviral activity, whether used alone or in combination with other antivirals, antiinfectives, immunomodulators or HIV entry inhibitors. More particularly, the present invention relates to the treatment of HIV and AIDS.